罗氏83亿收购美国制药公司InterMune

2014-08-29 17:33:53来源：可可英语

　　The acquisition represents a triumph for InterMune after a history of travails. A previousdrug being tested for pulmonary fibrosis failed in clinical trials. The company’s former chiefexecutive, W. Scott Harkonen, was convicted of wire fraud for issuing a news release thatprosecutors said was an effort to promote off-label sales of that drug. Then, in 2010 the Foodand Drug Administration rejected pirfenidone, asking for an additional clinical trial.

　　这次收购代表着InterMune长期艰苦努力后的一次胜利。该公司之前推出的一款肺纤维化药品的临床试验宣告失败。公司前首席执行官W·斯科特·哈尔克宁(W. Scott Harkonen)被判电信欺诈罪名成立，因为据检方称，他通过发布新闻稿来推动这款药物的超适应症销售。2010年，美国食品与药品管理局(Food and DrugAdministration)拒绝批准吡非尼酮，要求对其进行更多临床试验。

　　The merger is expected to close by year end. Mr. O’Day declined to say if there would belayoffs, though he said the main purpose of the merger was “growth synergies.”

　　这笔交易预计将于年底完成。奥黛拒绝透露公司是否会裁员，不过他说，收购主要是为了实现“增长的协同效益”。

　　Citigroup and the law firm Davis Polk & Wardwell advised Roche. Centerview Partners,Goldman Sachs and the law firm Cravath, Swaine & Moore advised InterMune.

　　为罗氏提供咨询服务的是花旗集团(Citigroup)和达维律师事务所(Davis Polk & Wardwell)。为InterMune提供咨询服务的是森特尔维尤合伙公司(Centerview Partners)、高盛(Goldman Sachs)和科瓦斯-斯怀恩-摩尔国际律师事务所(Cravath, Swaine & Moore)。

本文关键字: 罗氏83亿收购美国制药公司